Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders (CogMusT)

March 3, 2023 updated by: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Randomized, Single-blind Clinical Trial to Evaluate the Efficacy of Cognitive Rehabilitation Using Inmersive Virtual Reality and Computer-based Cognitive Stimulation Versus Music Therapy on Cognitive Impairment Associated With Movement Disorders

Mild cognitive impairment associated with movement disorders occurs in up to one third of patients in early stages of the disease, and confers an increased risk of developing dementia. Non-pharmacological interventions to improve cognition have so far been based on computer-based cognitive stimulation and rehabilitation programs. These interventions base their mechanism of action on neuroplasticity and how improvements in cognitive function will generalize to functional improvement.

Despite having shown certain indicators of efficacy in previous exploratory studies and clinical trials, cognitive rehabilitation continues to show insufficient evidence and requires further study.

To date, there are no previous studies using immersive virtual reality (IVR) to improve cognition. Both IVR and cognitive stimulation are based on the premise that they allow the simulation of ecological environments for rehabilitation than conventional rehabilitation, as well as being more efficient by allowing control of extraneous variables and providing safe spaces for patients. The only PD rehabilitation studies that have been conducted using IVR aimed to improve gait and balance disturbances compared to conventional physiotherapy treatment or non-immersive virtual reality (NIVR).

We hypothesize that a cognitive rehabilitation program using IVR or computer-mediated cognitive stimulation could have a greater beneficial effect on the cognitive status of patients with cognitive impairment associated with movement disorders compared to other modalities such as music therapy, delaying the worsening of cognitive functions.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive neuronal loss in the substantia nigra of the midbrain, as well as in other areas such as the pons, diencephalon, limbic system, and temporal cortex, which is accompanied by the deposition of alpha-synuclein in surviving neurons. (1) This neurodegeneration clinically manifests as motor symptoms (bradykinesia, rigidity, tremor) and non-motor symptoms (depression, anxiety, apathy, and cognitive impairment, among others).

Cognitive impairment associated with PD is currently recognized as one of the most relevant non-motor symptoms due to the significant impact it has on families and the economic cost it represents for public health. Dementia associated with PD is invariably preceded by a phase of mild cognitive impairment (MCI), characterized by the presence of alteration in neuropsychological tests without significant impact on the patient's functional capacity. Patients with MCI have a higher risk of developing dementia during the course of the disease. Specifically, conversion rates of 27.8% in the first year and up to 45.5% after 3 years have been described. (2)

Cognitive impairment associated with PD depends both on dopaminergic denervation of the nigrostriatal circuit (and secondary failure of fronto-subcortical circuits) and on the involvement of cholinergic brainstem structures, which project widely in the brain. (3) There is also growing evidence that cognitive impairment in PD is not only related to the deposition of alpha-synuclein, but that the deposition of beta-amyloid (characteristic of Alzheimer's disease) also plays an important role. (4)

Huntington's disease (HD) is a dominant autosomal neurodegenerative disease caused by an expansion of CAG in exon 1 of the gene that encodes for huntingtin on chromosome 4. This abnormal expansion of CAG gives rise to mutant huntingtin, considered the main protein involved in the pathophysiology of HD. (5) Individuals who carry the mutation and have ≥40 CAG repeats will inevitably show progressive motor (chorea, bradykinesia, and dystonia), cognitive (cognitive impairment and dementia), psychiatric (depression, apathy, perseverative behavior, irritability, among others), and functional deterioration in adulthood. The average age of onset of motor symptoms is around 45 years, and the course of the disease is approximately 10-20 years. (6)

Cognitive impairment associated with HD has been mainly attributed to progressive atrophy of the basal ganglia together with the disruption of fronto-subcortical circuits that accompany it. However, other diffuse brain changes, including alterations in cerebral white matter and posterior cortical atrophy, have also been shown to contribute to cognitive impairment. (7, 8)

The treatments currently available are basically symptomatic, and so far no drug has been found to alter the natural history of these diseases. (9) Finding a new target or treatment to reduce the progressive nature of the disease represents an important challenge from a scientific, healthcare, and social perspective. Specifically, acting effectively in the early stages of cognitive impairment in PD and HD to reduce the conversion rate to dementia would represent an immeasurable benefit.

The goal of cognitive rehabilitation is to improve a person's functional performance and compensate for cognitive deficits resulting from brain damage in order to reduce functional limitations, increasing people's ability to perform daily activities. (10) The ultimate purpose is to improve the quality of life of people. (11, 12)

Cognitive functions are interrelated and interdependent at an anatomical level when functional responses are required. They involve multiple types and levels of processing. When an external or internal activity is carried out, neuronal networks are combined, either modularly or through large-scale networks. These combinations recruit specific neuropsychological processes that are carried out for execution. From visual recognition to initiation processes of behavior (automatic or not), impulse control, or the development of metacognitive strategies that plan behavior. Therefore, from an applied point of view, formulating rehabilitation activities that cover the entire range of processes, discretely but also holistically, would be the appropriate way of application to achieve therapy that is as ecologically, customizable, and generalizable as possible.

The mechanism of action on which cognitive rehabilitation or stimulation programs are based is neuroplasticity. This is defined as the brain's ability to reorganize its patterns of neuronal connectivity by generating new synapses, adjusting its functionality. Neuroplasticity is present both in normal aging and in conditions of acquired brain damage or dementias. The greater efficacy of these types of programs has been found in patients with acquired brain damage (stroke, traumatic brain injury, among others) and to a lesser extent in the field of dementias, although it has shown some benefit compared to usual treatment. Today there is no established consensus regarding the effect that occurs by taking advantage of the plasticity phenomenon, as it depends on multiple factors: type of deterioration, age, recovery process, cognitive reserve, genetic factors, among others.

Plasticity can improve learning processes at three levels: a neuronal level, a synaptic level, and a network level (changes in functional connectivity). These levels are not mutually exclusive. The remodeling of short- and long-term neuronal activity patterns, including the formation, elimination, and change in firing frequencies and thresholds, as well as the sprouting of new axons, are the main ways to achieve neuronal organization through experience and maturation. Neurotrophic factors are also modified by experience through epigenetic regulation.

The effect that music therapy has on rhythm and its relationship to the motor aspects of the basal ganglia suggests that music therapy could be useful in the field of emotional complications of neurodegenerative diseases. Studies on music therapy in Parkinson's disease have shown efficacy and usefulness as therapy for speech rehabilitation or improvement of gait, posture, and balance. Since music therapy is not associated with significant adverse effects, music appears as a viable and attractive option as an active control treatment.

Conclusions:

Cognitive impairment associated with movement disorders has a significant negative impact on the autonomy and quality of life of both patients and families and makes them highly dependent on healthcare and social resources. The treatments currently available are basically symptomatic, and so far no therapy has been found to change the natural history of these diseases.

The lack of pharmacological strategies to stop or slow down cognitive decline associated with neurodegenerative diseases, specifically movement disorders, highlights the importance of developing non-pharmacological therapeutic strategies to change the course of cognitive decline and achieve greater functionality. Cognitive stimulation programs based on RVI or RVNI have the characteristic of creating ecologically valid environments that allow for practice based on the interaction of different cognitive processes depending on the task, and ultimately allow for generalization in daily life through learning and automation of routines or optimization of neural networks, generation of new synapses, and changes in neuronal firing that allow for neuroplasticity.

So far, evidence on cognitive rehabilitation in the field of movement disorders is based on cognitive stimulation studies involving the repetition of tasks focused on one or more cognitive processes without clear ecological validity, or in studies based on virtual reality that are limited to improving motor function in Parkinson's disease (24, 25, 26, 27, 28). To date, the heterogeneity in the conceptualization of cognitive decline in movement disorders without following consensus criteria for including patients in clinical trials has led to demonstrating limited efficacy or non-comparability with other studies. The importance of correctly classifying patients based on their cognitive status is crucial for the proper design of trials aimed at improving cognitive function in movement disorders (7, 26, 29, 30).

Therefore, we have designed a study focused on evaluating the effect of cognitive rehabilitation based on RVI and computer-based cognitive stimulation on cognitive decline in movement disorders. Given the natural history of these types of diseases, we have the possibility of detecting cognitive changes in a relatively short period of time using appropriate tools (31, 32). The PD-CRS has been shown to be capable of detecting changes in cognitive status in Parkinson's disease and Huntington's disease over time (good sensitivity to change), being able to detect clinically relevant differences in a period of 6 months. To assess clinical relevance, the Clinical Global Impression of Change scale was used, with a change of 11-14 points in the PD-CRS being the minimum to consider that there is a clinical impact. For this reason, we consider that a single-blind clinical trial of 6 months duration would be sufficient to demonstrate significant differences between the cognitive performance of the control group (music therapy) and the RVI or computer-based cognitive stimulation group.

Study Type

Interventional

Enrollment (Anticipated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Barcelona, Spain, 08025
        • Hospital de la Santa Creu i Sant Pau

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient capable of understanding, signing and dating the written informed consent at baseline visit prior to randomization.
  • Patient diagnosed with Parkinson's disease (Movement Disorder Society PD Criteria) or Huntington's disease.
  • Patient with Hoehn and Yahr stage I-III for PD, and Shoulson and Fahn stage I-II for HD.
  • Patient with a score on the Parkinson's Disease Cognitive Rating Scale (PD-CRS) >83, who present subjective memory complaints will be included in "group I: subjective memory complaints".
  • Patient with a score on the Parkinson's Disease Cognitive Rating Scale (PD-CRS) between 64 and 83, both inclusive, will be included in "group II: mild cognitive impairment".
  • Patient diagnosed with Parkinson's disease with stable dopaminergic treatment in the last 4 weeks.
  • Patient capable and willing to comply with study visits as detailed in the protocol.

Exclusion Criteria:

  • Illiterate patients.
  • Patients with severe vision or hearing impairment.
  • History of deep brain stimulation surgery.
  • Patients diagnosed with severe dementia (possible or probable) associated with Parkinson's disease, according to the Clinical Diagnostic Criteria for Dementia Associated with PD with a score of >2 on the CRD or with Huntington's disease.
  • Patients with active psychosis in the form of incapacitating delusional ideation.
  • Patients who were under experimental treatment in the 2 months prior to the selection period.
  • Patients with any of the following conditions:
  • Life expectancy of less than 6 months.
  • Any severe or uncontrolled medical condition.
  • Patients with a history of poor treatment compliance or drug/alcohol abuse that may interfere with the patient's ability to comply with the study protocol or give informed consent.
  • Pregnancy or breastfeeding.

  • Contraindications for MRI*.

    • Except for patients with Parkinson's disease (PD), since MRI is optional for these patients. Therefore, if there are contraindications for MRI, they can still participate without undergoing MRI.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Immersive Virtual Reality (Parkinson's disease)
Device: Immersive Virtual Reality (Parkinson's disease)
This tool involves placing sensors in the space where it will be used, wearing virtual reality glasses, and using controllers to create realistic fictional spaces and interact with them. The program used for the study consists of an interface and a set of tasks designed specifically for the type of cognitive process deficits related to frontal function (executive functions) that are predominantly presented by patients with cognitive impairment associated with Parkinson's disease. This is due to the effect of the disease's pathophysiology on a series of brain circuits and structures that range from the basal ganglia to the frontal lobe. The affected functions correspond to the individual's ability to plan, sequence, organize, make decisions, be flexible, abstract, conceptualize, inhibit, among others.
Active Comparator: Computer-based cognitive rehabilitation (Parkinson's disease)
Device: Computer-based cognitive rehabilitation (Parkinson's disease)
This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
Experimental: Computer-based cognitive rehabilitation (Huntington's disease)
Device: Computer-based cognitive rehabilitation (Huntington's disease)
This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
Active Comparator: Music-therapy (Huntington's disease)
Behavioral: Music-therapy (Huntington's disease)
The process used in each session will be standardized, while the content will be flexible, administering the guidelines according to the mood of the patients and their needs at that time. The therapist's clinical experience will guide them, providing sufficient space for flexible adaptation within the treatment guideline. While the sessions will be standardized, without limiting the music therapist in their interactions, the intervention itself will be applied during the experimental period, using all of the cognitive music therapy exercises detailed below in all groups: auditive perception training, musical sensorial orientation, control of musical attention, training of musical executive function, training in musical mnemotecnia and associative training of mood and musical memory

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Parkinson's Disease - Cognitive Rating Scale (PD-CRS)
Time Frame: 24 weeks
24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 13, 2021

Primary Completion (Actual)

September 21, 2022

Study Completion (Anticipated)

December 1, 2023

Study Registration Dates

First Submitted

March 3, 2023

First Submitted That Met QC Criteria

March 3, 2023

First Posted (Actual)

March 15, 2023

Study Record Updates

Last Update Posted (Actual)

March 15, 2023

Last Update Submitted That Met QC Criteria

March 3, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IIBSP-MOV-2021-28

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Immersive Virtual Reality (Parkinson's disease)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe